Výsledky vyhledávání - "Denise Röllig"

Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas

Autor: Frank Kroschinsky, Michael Kramer, Denise Röllig, Barbara Riemer, Johannes Schetelig, Gerhard Ehninger, Mathias Hänel, Martin Bornhäuser, Rainer Ordemann

Publikováno v: Journal of cancer research and clinical oncology. 145(12)

The combination of dexamethasone, high-dose cytarabine, and cisplatin (DHAP) is an established salvage regimen for lymphoma patients. We hypothesized that a modified administration schedule for cisplatin and cytarabine results in lower toxicity and i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e7d7734d23faf6151f5b393ae754c94
https://pubmed.ncbi.nlm.nih.gov/31563974

Zobrazit plný text záznamu

Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry

Autor: Vera Gelbricht, Denise Röllig, Christina Köhler, Eberhard Kuhlisch, Sebastian Werth, Jan Beyer-Westendorf, Franziska Ebertz, Norbert Weiss, Thomas Schreier, Thoralf Stange, Luise Tittl, Ingolf Röder, Christoph Thieme, Kati Förster, Ulrike Hänsel

Publikováno v: British Journal of Clinical Pharmacology. 78:908-917

Aim Vitamin-K antagonists (VKA) and non-vitamin-K dependent oral anticoagulants (NOAC) have been approved for anticoagulation in venous thromboembolism (VTE) and atrial fibrillation and patients previously treated with VKA are switched to NOAC therap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e72c15fed3e29a163e9a490adae30aca
https://doi.org/10.1111/bcp.12391

Zobrazit plný text záznamu

Pattern and Management Of Bleeding Complications With Novel Oral Anticoagulants – Results Of The Prospective Dresden Noac Registry (NCT01588119)

Autor: Franziska Ebertz, Denise Röllig, Vera Gelbricht, Christina Köhler, Jan Beyer-Westendorf, Kati Förster, Luise Tittl, Sebastian Werth

Publikováno v: Blood. 122:214-214

Background The most common side effect of oral anticoagulants are bleeding complications. In large trials, novel direct oral anticoagulants (NOAC) have been shown to reduce the risk of major bleeding compared to warfarin. However, little is known abo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e49980f78d82e546017d8dfb82d3ca5
https://doi.org/10.1182/blood.v122.21.214.214

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání